GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.

Date publication

juillet 2020

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique , Mme POZET Astrid

Tous les auteurs :
Selle F, Heudel PE, Hardy-Bessard AC, Pozet A, Meunier J, Gladieff L, Lotz JP, Provansal M, Augereau P, Berton D, Bonichon-Lamichhane N, Orfeuvre H, Pautier P, Kalbacher E, Tazi Y, Spaeth D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32620635

Résumé

Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.

Mots clés

Ovarian cancer, pegylated liposomal doxorubicin, platinum-sensitive, trabectedin

Référence

Anticancer Res.. 2020 Jul;40(7):3939-3945